Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
Public ClinicalTrials.gov record NCT03057600. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in participants of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839 will be administered in combination with the full approved dose of paclitaxel.
Study identification
- NCT ID
- NCT03057600
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 52 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1, 2017 (Actual)
- Primary completion
- Nov 25, 2019 (Actual)
- Completion
- Nov 25, 2019 (Actual)
- Last update posted
- Sep 28, 2022
2017 – 2019
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Brimingham | Birmingham | Alabama | 35294 | — |
| University of South Alabama, Mitchell Cancer Institute | Mobile | Alabama | 36604 | — |
| Yale Cancer Center | New Haven | Connecticut | 06511 | — |
| Georgetown University - Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Washington Cancer Institute | Washington D.C. | District of Columbia | 20010 | — |
| University of Miami | Miami | Florida | 33176 | — |
| Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| University Cancer and Blood Center | Athens | Georgia | 30607 | — |
| Winship Cancer Institute - Emory University | Atlanta | Georgia | 30332 | — |
| Northwest Georgia Oncology | Marietta | Georgia | 30060 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Weinberg Cancer Institute at Franklin Square | Baltimore | Maryland | 21237 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Saint Louis University | St Louis | Missouri | 63110 | — |
| JTCC at Hackensack UMC | Hackensack | New Jersey | 07601 | — |
| Columbia University | New York | New York | 10032 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Magee Womens Hospital - UPMC | Pittsburgh | Pennsylvania | 15213 | — |
| Charleston Hematology Oncology Associates | Charleston | South Carolina | 29414 | — |
| Greenville Health System (GHS) Cancer Institute | Greenville | South Carolina | 29605 | — |
| West Cancer Center | Germantown | Tennessee | 38138 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
| Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03057600, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2022 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03057600 live on ClinicalTrials.gov.